Please login to the form below

Not currently logged in
Email:
Password:

Pfizer cuts 6,000 jobs

Following the acquisition of Wyeth last year, Pfizer has confirmed that up to 18 per cent of its global workforce - 6,000 jobs - will be cut

Following the acquisition of Wyeth last year, Pfizer has confirmed that up to 18 per cent of its global workforce - 6,000 jobs - will be cut. These reductions are part of efforts to streamline the company and form part of the 19,000 jobs Pfizer said it would eliminate after its $68bn acquisition. They come alongside the closure of eight of the group's 78 factories in North America and Europe.

The eight manufacturing sites, in Ireland, Puerto Rico and the US, will close by the end of 2015 and operations will be reduced at six other plants in Germany, Ireland, Puerto Rico, the UK and the US.

"The restructuring of our global plant network is critical to our efforts to remain competitive," said Nat Ricciardi, Pfizer's global manufacturing president.

The company will attempt to restrict the impact on communities by selling assets, rather than closures, where possible.

In November 2009, Pfizer announced the closure of six research centres.

19th May 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

EU health fund
An EU emergency health fund to limit the impact of future crises
Leading finance experts propose an Emergency Health Financing Facility to limit the impact of future crises on the EU...
Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...

Infographics